Skip to main content

Diabetes

  • Abbott Diabetes Care reports blood-glucose monitoring products stolen

    ALAMEDA, Calif. — Abbott Diabetes Care reported Friday that a shipment of blood-glucose monitoring products was reported stolen from a shipping carrier facility in Louisville, Ky., on June 19.

  • Adding Byetta to diabetes regimen could cut heart failure risk

    SAN DIEGO — Use of a drug for Type 2 diabetes made by Eli Lilly and Amylin Pharmaceuticals may lower patients’ risk of heart failure, according to a new study.

    The study of more than 778,000 patients taking the injected drug Byetta (exenatide) found that adding the drug to a pre-existing diabetes regimen, especially if that regimen included insulin, was associated with reduced likelihood of heart failure. Results were presented Saturday at the 71st Scientific Sessions of the American Diabetes Association in San Diego.

  • Report: Some branded diabetes drug prices at Walmart, Kmart rise at fast rate

    NEW YORK — Prices for the top 10 most prescribed branded diabetes drugs have risen faster at Walmart and Kmart than at other retailers, according to a published report.

    Citing a recent study by researchers at the Mount Sinai Medical Center in New York, Reuters reported that Walmart raised prices for branded diabetes drugs by 32% between 2008 and 2010, compared with 21% for the industry as a whole — including independent and chain retail pharmacies and mail-order companies. Kmart raised prices by 35%.

  • Novo Nordisk's Victoza helps patients achieve blood-sugar control when switching from exenatide or sitagliptin

    SAN DIEGO — Novo Nordisk unveiled data from two extension studies at the 71st annual Scientific Sessions of the American Diabetes Association in San Diego that show its diabetes drug, when combined with other medications, may help patients achieve blood-sugar control.

    The drug maker found that combining Victoza (liraglutide [rDNA origin] injection) with metformin and/or sulfonylurea helped patients achieve blood-sugar control.

  • Nipro showcases diabetes-friendly energy shot

    BOSTON — Nipro Diagnostics is building around its co-branded blood-glucose meter with a line of glucose-control products, including its TruePlus glucose shot.

    The entire line also includes a glucose tablet product, a glucose gel and a diabetes-friendly multivitamin. But it's the diabetes-friendly energy shot that should garner the most interest, because that will be the acceptable delivery format for the next generation of diabetics.

  • Commonly used arthritis drugs may cut diabetes risk among patients, study finds

    NEW YORK — Patients with inflammatory conditions may have lower rates of diabetes if they take drugs commonly used to treat arthritis, according to a new study published in the Journal of the American Medical Association.

    The study, conducted by researchers at Brigham and Women’s Hospital in Boston, examined nearly 14,000 patients with rheumatoid arthritis and psoriasis who took disease-modifying anthrheumatic drugs. Patients who have these diseases have significantly increased risk of developing cardiovascular disease and diabetes.

  • Diabetic kidney disease on rise in United States

    NEW YORK — Despite the expansion of the diabetes drug market over the past 20 years, the rate of diabetic kidney disease has become more prevalent in the United States.

  • BMS donates grants to help African-American women fight Type 2 diabetes

    NEW YORK — The charitable arm of Bristol-Myers Squibb has awarded five grants totaling $1.5 million to organizations that encourage African-American women with Type 2 diabetes to better manage their disease.

X
This ad will auto-close in 10 seconds